

Index

a

- acceptance criteria 444–445
 - for equivalence testing
 - advanced approach 450–457
 - case-by-case selection 455
 - generic approach 450
- accuracy, ICH 147–148
- active pharmaceutical ingredient (API)
 - 72, 119, 221, 373, 444, 491
- Akaike information criterion (AIC) 277, 326
- ALCOA+, GCP Guidance 22, 23
- analysis of variances (ANOVA) 114, 122–125, 325, 458
- Analytical Development and Quality Control 16
- analytical instrument qualification (AIQ) 51
 - analytical procedure lifecycle 37–38
- GAMP
 - analytical apparatus, instruments and systems 44–45
 - data quality triangle 45
 - granularity of USP 43–44
 - software categories 45
 - terminology clarification 44
- group B and C systems 43
- importance of 51
- risk-based approaches
 - eight enhance categories 48–49
 - instrument and system categories 46–48
- United States Pharmacopoeia
 - apparatus, instruments and systems 40–41
 - data quality triangle 39
 - 4Qs model 39–40
 - roles and responsibilities 42–43
- Analytical Instrument Qualification and System Validation (AIQSV)
 - 19–21, 35–49
- analytical performance
 - analytical performance review (APR) 504–508
 - average performance parameters 501–503
 - immediate actions 503–504
 - sources of performance data and information
 - batch results 491
 - parameter from sample analysis 491
 - precisions from stability 491–493
 - quality control samples (QCS) 491
 - reference standard analysis 490
 - system suitability test parameters 490
 - systematic monitoring program 493–495
 - visualization charts 496–501
- analytical performance review (APR) 504–508
- analytical procedure control strategy (APCS) 8, 118, 167, 220, 228–229, 303, 345, 349, 402–3, 423, 428, 471–473, 482, 488

Method Validation in Pharmaceutical Analysis: A Guide to Best Practice, Third Edition.

Edited by Joachim Ermer and Phil W. Nethercote.

© 2025 WILEY-VCH GmbH. Published 2025 by WILEY-VCH GmbH.

- analytical procedure lifecycle (APL) 5, 7, 16, 20, 21, 37–38, 219, 220, 354, 355, 357
- analytical procedure performance
 - characteristics (APPCs) 421
- analytical procedures 5, 79
 - acceptable precision for assay 130–136
- accuracy
 - acceptance criteria 163–164
 - comparison 149
 - direct comparison 152–153
 - equivalence tests 151–152
 - maximum expected random difference 165
 - precision evaluation 160–163
 - precision, response, and specificity 148
 - sample and reference standard solutions 166
 - sample size for equivalence test 154–155
 - significance tests 149–151
 - spiking studies 155
- automated DDU procedure 400
- complex dosage forms 391
- delivered dose uniformity testing for
 - inhalation products 392
- detection and quantitation limit 193–205
- dose recovery and sample preparation 400
- human and environmental factors 391–392
- noise factors associated with dose collection 398
- precision
 - acceptance criteria 130–146
 - analysis of variances 122–125
 - concentration dependency 127–130
 - intermediate precision and reproducibility 114–116
 - levels 112–121
 - from linear regression 125
 - log-normal distribution 108–109
 - mass balance approach 126–127
 - measurement uncertainty 125–127
 - normal distribution and parameters 99–108
 - repeatability 113–114
 - reportable range 146
 - reportable result 116–121
 - system or instrument precision 112–113
 - and variances calculation 121–128
- response-calibration model 175–176
- specificity/selectivity
 - by accuracy 169
 - chromatographic resolution 170–171
 - detection 168
 - peak purity/co-elution 171–174
 - sample preparation 168–169
 - stress samples 169
- Analytical Procedures and Methods
 - Validation for Drugs and Biologics 301, 480
- analytical procedures validation
 - lifecycle of 356–358
 - multivariate 358–359
 - reportable range 357–358
 - stability-indicating properties 358
 - study 356
- analytical target profile (ATP)
 - components of 72–73
 - DDU procedure 392–401
 - feasibility testing 430
 - key performance indicators 89–90
 - method development 240–251
 - method optimization 251–261
 - method selection 239
 - metrics for assessment 74–76
 - performance qualification 431–432
 - probability statements 73–74
 - requirements 431
 - sampling strategy 240
- analytical transfer process
 - comparative testing 446
 - coordination of transfer activities 441

design of experimental studies and
 acceptance criteria 444–445
 familiarization and training 443–444
 lifecycle approach 471
 regulatory and international guidance
 435–440
 result evaluation 445
 transfer strategy 441–443
 analytical transfer team (ATT) 441
 appropriate calibration model
 area% quantitation 190–191
 matrix impact 191
 non-linear response 191–192
 single-point calibration 189–190
 artificial neural networks (ANN) 284
 automated DDU procedure
 actuation 400
 shaking 400
 average performance parameters
 501–504

b

Bartlett's test 188
 Bayesian information criterion (BIC)
 277, 326
 bioassay method
 accuracy 411–412
 cell-based relative potency assay
 405
 material considerations 407
 precision 412
 intermediate precision 412–413
 repeatability 413–415
 reproducibility 415
 range 415–416
 robustness 416–417
 specificity/selectivity 410–411
 stability-indicating properties
 410–411
 study design 407–410
 validation study 407, 408
 BioPhorum Operations Group (BPOG)
 494–495
 box-and-whisker plot 110, 507
 Box-Cox method 327, 330

c

calibration model
 appropriate 189–191
 calibration highlights 192–193
 confidence and prediction intervals
 graphical evaluation 180–182
 numerical regression parameters
 182–184
 sensitivities 181–182
 statistical linearity tests 184–185
 systematic errors 186–187
 non-linear response 191–192
 requirements 175
 unweighted linear regression 177–187
 weighted linear regression 187–189
 calibration–prediction–verification 305
 capability index 101, 134, 135, 449, 507
 central limit theorem 85, 101, 109
 Certification of Suitability (CEP) 421,
 422
 chemometric model 265, 266, 267, 287
 chemometrics 265, 266, 275, 280, 284,
 285, 287
 chromatography data system (CDS) 23,
 26, 59, 63
 chromatography modelling software
 305–312
 classical least squares (CLS) 278
 cluster analysis 279–281
 Cochran's test 188
 coefficient of correlation/determination
 55, 178, 182ff, 193, 289, 322, 361,
 415, 498
 coefficient of variation (CV) 108, 119,
 121, 322, 365, 375, 412, 413, 444,
 452
 commercial software packages 457, 458
 comparative testing
 direct comparison
 accuracy 466–468
 precision 465–466
 equivalence-based methodology
 acceptance criteria for equivalence
 testing 449–457
 decision procedure 458–461

- comparative testing (*contd.*)
 - drug product assay method 461–462
 - interlaboratory study 447–448
 - principle 446–447
 - statistical analysis 457–458
 - transfer endpoints 448–449
 - water content method 462–465
- compendial/pharmacopeia test
 - procedures
 - background of 419
 - challenges with 420–421
 - generated and published 420
- computer-assisted robustness studies 304–338
- confidence intervals (CI) 98, 106–108, 161, 178, 285, 303, 364–367, 370, 375, 415, 444, 473, 484, 492, 493
- conformity 488, 494, 504, 505
- continuous performance qualification (cPQ) 53
- control chart 59–61, 63, 104, 441, 474, 496–501, 503, 506
- control chart limits 111, 121, 474, 501, 505, 506
- control of change, pharmaceutical industry 480–483
- control strategy, defined 345
- coordination of transfer activities 441
- correlation coefficient 280
- critical process parameters (CPPs) 267
- critical quality attributes (CQAs) 71, 79, 97, 221, 268, 318, 353, 392, 446
- cross-validation methods 287
- current good manufacturing practices (cGMP) 436, 480
- d**
 - data-driven methods 273, 274
 - data governance 15
 - AIQSV 19–20
 - data integrity model 16–21
 - foundation 17–19
 - four levels model 16–17
 - outsourcing analysis 19
 - policies and procedures 18
 - quality culture and working environment 19
 - quality oversight 19
 - right analytical result 20
 - roles and responsibilities 18
 - senior management involvement 18
 - data integrity 15, 35
 - ALCOA criteria for 22–23
 - analytical procedure 23
 - chromatography instrumental analysis 26–27
 - corporate culture for 16
 - foundation layer 23
 - four eyes principle 28
 - instruments and systems used 24–25
 - overview of 21–22
 - peak integration 27
 - quality oversight for 20–21
 - reportable result 27–28
 - sample preparation 25, 26
 - software applications validation lifecycle 35
 - time synchronisation 25
 - data preprocessing 271–273
 - data quality 15
 - criteria for 35–37
 - elements 37
 - decision rules 7, 81–82
 - analytical target profile 88
 - bias and uncertainty 89
 - and compliance 82–83
 - measurement uncertainty 90–94
 - procedure performance 82
 - target measurement uncertainty 83–86
 - types of
 - use guard bands 87–88
 - use transition rules 88
 - USP 94
 - degrees of freedom 58, 101, 103, 104, 107, 108, 114, 115, 116, 122, 150, 152, 179, 288, 315, 320, 366, 369, 452, 453, 457, 458, 484, 502

- delivered dose uniformity (DDU)
 - 392–393
 - actuation profile experiments
 - 397–398
 - control strategy 402–403
 - device preparation 394
 - dose collection 394–396
 - experimental factors associated, dose
 - collection 396
 - performance characteristics
 - 401–402
 - qualification of 402
 - shaking profile experiments 396–397
- design of experiments (DoE)
 - classification types 313
 - confounding/aliasing 315
 - factor levels 315–318
 - mathematical model 318–319
 - mixture-related factors 317–318
 - qualitative factors 316–317
 - Rechtschaffner design 328
 - responses of 318
 - results, final model 333
 - robustness testing 312–314
 - statistical analysis, model building
 - 328–333
- digitalisation 26
- diode array detector (DAD)-UV 245
- direct comparison 152–153
 - accuracy 466–468
 - precision 465–466
- DL/QL linear response
 - German Standard DIN 32645 202
 - standard deviation 200–201
- dose collection 393–400
- drivers for change 479–480
- drug product assay method 461–462
- DryLab 304–312
- e**
 - electronic notebook (ELN) 401
 - empirical models 265, 318–319
 - equipment qualification (EQ) 51, 112, 113
 - equivalence-based methodology
 - acceptance criteria for equivalence
 - testing 449–457
 - decision procedure 458–461
 - drug product assay method 461–462
 - interlaboratory study 447–448
 - principle 446–447
 - statistical analysis 457–458
 - transfer endpoints 448–449
 - water content method 462–465
 - equivalence tests 151–157, 163, 167, 185–187, 364–367, 371, 375, 438, 440, 441, 448–459, 471, 474
 - error propagation 98, 125–128, 190, 242, 253
 - European Good Manufacturing Practice (EU GMP) Guide Quality Control 436
 - European Medicines Agency (EMA) 1, 266, 436
 - European Pharmacopeia (Ph. Eur.) 419, 483
 - exploratory data analysis
 - cluster analysis 279–281
 - outliers detection and handling
 - 278–279
 - principal component analysis
 - 275–278
 - extracted chromatography conditions
 - 305
- f**
 - failure mode effect analysis (FMEA)
 - 229, 347, 398
 - dose collection noise factors 399
 - extract 348
 - familiarization and training 435, 443, 444
 - Fishbone diagram
 - device preparation 394
 - dose collection 394–396
 - Fisher test 58
 - Food and Drug Administration (FDA)
 - process validation 1–3
 - regulation 2
 - 4Qs model 39–40, 43

g**GAMP**

- analytical apparatus, instruments and systems 44–45
- risk-based approach to instruments 43–45

gas chromatography (GC) solvent screen method 479

gathering knowledge 426

- analytical procedures 425, 428

- ATP 429–431

- instruments settings 425

- intended purpose of 424–425

- monograph 425–428

- trial study 428–429

General Chapter <1058> of USP 52

genetic algorithms (GAs) 275

geometric coefficient of variation (GCV) 108, 412, 413

geometric standard deviation (GSD) 408

goal-seek-function 201

good manufacturing practice (GMP)

- environment

- data integrity and data quality 35–37

- qualified analytical instruments and validated systems 37

Good Practice Guide on Technology

- Transfer 436, 438

Graybill–Wang modified large sample (MLS) method 457

guard band 81, 82, 86–88, 94, 95, 136

h

hazard identification 343–345

heat map 347, 348, 494

hierarchical cluster analysis (HCA) 280

high-performance liquid chromatography (HPLC)

- analytical instrument qualification 51

- continuous performance qualification (cPQ) 53, 61–65

- degradation products 378–379

- detector 56–57

- experimental study 375–377

- holistic approach, autosampler 55

limit of quantitation (LOQ) 388–389

OQ/PQ data vs. SST data 58–59

OQ/PQ parameters list 53–55

parameters and drug product 374

reportable range 389

solvent delivery system 55–56

trending plots/control charts 59–61

validation methodology

- accuracy 384–385

- calibration model 384

- DP1 spiked test 386

- intermediate precision 387–388

- linearity study results 382

- repeatability 385–386

- specificity 380–382

- system precision 386–387

validation summary 377–380

high-performance size exclusion chromatography (HPSEC) method 328

holistic approach autosampler 55

HorRat value 127

Horwitz function 129, 136

Hotelling's T^2 276, 278, 279, 285

Hubert states method 73

i**ICH Q2**

analytical procedures validation

- lifecycle of 356–357

- multivariate 358–359

- reportable range 357–358

- stability-indicating properties 358

- study 356

- types of 357

- validation characteristics 356

analytical techniques 367–370

validation tests, methodology

- accuracy 364–367

- precision 364–367

- range 360–364

- robustness 367

- specificity/selectivity 359–360

ICH Q9 35, 252, 343–345, 347, 425

ICH Q10 2, 232, 345, 349

ICH Q12 5, 220, 229, 232, 233, 481, 482

ICH Q14

analytical procedure control strategy
228–229

analytical target profile 220–222

connection between product and
analytical procedure 222–223

lifecycle strategy 229–232

link and impact 227–228

method operable design region
(MODR) 226–227

prior and platform knowledge
223–226

scope of 221

ICH validation guideline 147, 161

implications and opportunities of

Applying QbD Principles to

Analytical Measurements 481

indexed quality by design (iQbD) 425

information extraction 266

innovation and continuous improvement

in pharmaceutical manufacturing
479, 480, 481

in-process control (IPC) 239, 268, 345,
349, 370, 444

intermediate precision 99, 112, 114–116,
119–123, 125, 130, 131, 135, 142,
143, 145–147, 153, 154, 164, 257,
303, 355, 365, 366, 368–370, 375,
380, 384, 386–388, 402, 403, 406,
407, 412–413, 415, 417, 431, 437,
444, 446–462, 465, 467, 488, 493,
497

internal release limit 87

International Society of Pharmaceutical
Engineering (ISPE) 436

interquartile range (IQR) 109

interval-PLS (i-PLS) 274

Ishikawa/fishbone diagrams 347, 394,
395, 460

k

Karl-Fischer titration 157, 270

key predictive sample set (KPSS) 242

k-means clustering 280

K-nearest neighbors (*k*-NN) 285

l

laboratory execution system (LES) 25

laboratory information management
system (LIMS) 26, 46, 401,
492

Lambert–Beer law 176, 278

LC-Simulator software 248

lean transfer strategy 473, 474

least-squares regression 176, 177, 188

lifecycle approach

analytical procedure control strategy
(APCS) 472–473

lean transfer strategy 473–474

risk assessment 472

limit of quantitation (LOQ) 228, 253,
373, 388, 406

linear regression 98, 102, 114, 125, 155,
166, 177–187, 191–193, 196, 198,
199, 200, 202, 274, 303, 361, 364,
380, 383, 388, 407, 493

liquid chromatography (LC) 60, 99, 221,
239, 472, 494, 501

log-normal distribution 108, 109, 117,
130

lower specification limit (LSL) 131, 375,
449, 453

m

Mahalanobis distance 278, 280, 284

main component (MC), accuracy of
384–385

Marfey's reagent 168

marketing authorisation holder (MAH)
232, 481

mass balance approach 126–127, 149

mass spectrometry (MS) 148, 239, 266,
359, 368, 380

mathematical model

criteria based on design 319

criteria based on model estimation
320–322

criteria based on prediction 322

empirical models 318–319

mechanistic models 318

mathematical/statistical model 314

measurement uncertainty (MU) 7,
 79–81, 83–85, 87–94, 98, 125–127,
 190
 mechanistic model 313, 318
 metered dose inhalers (MDIs) 391–403
 method operable design region (MODR)
 226–227, 253, 316, 402, 481
 model calibration
 qualitative 284–286
 quantitative 281–284
 model maintenance 289–292
 monoclonal antibody (mAb) 221, 368
 multiple linear regression (MLR) 274,
 282
 multiplicative scatter correction (MSC)
 271
 multivariate analytical procedures
 data preprocessing 271–273
 exploratory data analysis
 cluster analysis 279–281
 outliers detection and handling
 278–279
 principal component analysis
 275–278
 model calibration
 qualitative 284–286
 quantitative 281–284
 model maintenance and lifecycle
 management 289–292
 model optimization and validation
 cross-validation 286–288
 mode performance assessment
 288–289
 pharmaceutical industry
 control strategy development phase
 268
 process validation and lifecycle
 strategy phase 268–269
 product and process design phase
 267–268
 sampling and data quality 269–271
 variable selection 273–275
 multivariate calibration 265, 281, 358,
 362
 multivariate statistical process control
 (MSPC) 268

n

network time protocol (NTP) 25
 nonlinear iterative partial least squares
 (NIPALS) 277
 nonlinear responses 191–192, 201, 362,
 371
 normal distribution, parameters 99–108
 normal distribution probability
 130–131, 465
 numerical analytical control parameters
 488

o

one-factor-at-a-time (OFAT) 303
 operational qualification (OQ) 40, 52,
 303
 OQ/PQ
 data vs. SST data 58–59
 parameters list 53–55
 orthogonal PLS-DA (OPLS-DA) 286
 orthogonal signal correction (OSC) 272
 outlier test 110–111, 179, 180, 266, 276,
 278–279, 289
 out-of-specification (OOS) 19, 24, 59, 60,
 87, 106, 109–111, 222, 261, 397,
 424, 441, 449, 487, 488
 out of trend (OOT) 61–63, 397

p

Parenteral Drug Association (PDA) 124,
 354, 436
 partial least squares-discriminant analysis
 (PLS-DA) 286
 partial least squares (PLS) regression
 272, 283
 peak purity/co-elution
 diode array detection 172
 re-chromatography 171–172
 LC-MS 171–173
 performance qualification 8, 40, 52, 219,
 423, 428, 431–432, 471
 performance threshold 488
 pharmaceutical impurity determination
 accuracy and precision-based
 approaches 204

- DL/QL from linear response 198–200
 - general quantitation limit 194
 - intermediate quantitation limit 194–195
 - quantitation limit 204–205
 - signal-to-noise ratio 195
 - pharmaceutical industry
 - control strategy development phase 268
 - process validation and lifecycle strategy phase 268–269
 - product and process design phase 267–268
 - pharmaceutical lifecycle
 - analytical 7–9
 - AQbD approach 5
 - predefined objectives 5–7
 - process development 1–3
 - three-stage approach 3–5
 - pharmaceutical quality system (PQS) 2, 16, 17, 18, 30, 219, 232, 290, 493
 - pharmacopeia test procedures
 - implementation of 424–431
 - in laboratory 421–422
 - lifecycle approach 423
 - verification of 422–423
 - platform analytical procedure/
 - method 224, 228, 233, 354, 355, 370
 - post-approval change management
 - protocol (PACMP) 232, 233, 481, 482
 - pre-approval inspections (PAIs) 21
 - precision
 - bioassay method
 - intermediate precision 412–413
 - repeatability 413–415
 - reproducibility 415
 - reportable range and 146
 - precision acceptance criteria
 - acceptable precision 136–137
 - empirical approach 130
 - impurities and minor components 136–137
 - LC-intermediate precision/
 - reproducibility 145–146
 - LC repeatability 143–145
 - LC-system precision 137
 - misclassification approach 132–134
 - normal distribution probability 130–131
 - precisions benchmarks 137–143
 - specification limits 135
 - tolerance interval approach 134–135
 - prediction interval 103, 161–163, 179–180, 199–204, 366, 367
 - principal component analysis (PCA) 272, 275–278
 - Principal Component Regression (PCR) 283
 - prior knowledge 192, 220–233, 273, 279, 284, 355, 394, 473
 - probability density function 84, 100
 - probability of error 150
 - probability of results 76, 130, 131, 147
 - process analytical technology (PAT) 229, 266, 268, 482
 - process flowchart 345, 346, 441
 - process mapping 345–346
 - proficiency testing (PT) 92
- q**
- quality assurance (QA) 2, 17, 42, 227, 355, 441, 480
 - quality by design (QbD)
 - approach 79, 471
 - fitness for intended use 80–81
 - principles of 219
 - tools 237
 - quality control function 480
 - quality control samples (QCS) 473, 491
 - quality risk management (QRM) 2, 35, 343–345, 347, 394, 436, 493
 - quality target product profile (QTPP) 5, 71, 220, 221, 267
 - quantitation limit (QL) 6, 8, 65, 97, 129, 193–205, 363
 - quantitative factors 315, 316, 318, 328
 - quantitative models 281–284, 288

r

range, bioassay method 415–416
 real-time release testing (RTRT) 220, 267
 regression methods 326
 regulatory and international guidance 435–440
 relative accuracy 148, 488
 relative potency method 407
 relative RMSE 178, 183, 193
 relative standard deviation (RSD) 65, 99, 101, 121, 257, 365, 429, 437
 repeatability 59, 99, 105, 112–116, 118, 121–123, 128–130, 135, 136, 143–147, 154, 155, 162, 164, 180, 190, 323, 365, 366, 369, 375, 380, 385–387, 389, 401, 406, 407, 412–415, 417, 444, 447, 450, 453–455, 458, 461, 462, 467, 468, 472, 488, 492, 497–499, 505, 506
 replication strategy 80, 116ff, 131, 136, 229, 366, 405, 488ff
 reportable result 6, 23, 30, 72, 79, 111, 116ff, 131ff, 163, 175, 221, 345ff, 357ff, 373, 406, 429, 445, 466, 488, 502
 reporting limit (threshold) 136, 186, 194, 198, 205, 357, 363, 370, 375ff, 447, 455, 466
 residual plot 55, 177, 180–192, 279, 361, 370, 383, 415, 493
 residual sum of squares (RSS) 178, 327
 response surface methodology 314
 response surface model (RSM) 304
 result equivalence 483
 reversed-phase high-performance liquid chromatography (RP-HPLC) 244
 reversed-phase liquid chromatography (RP-LC) 242
 Right-First-Time approach 268
 risk analysis 343, 347–348
 risk identification/hazard identification 344–347
 risk management
 analytical procedure control strategy 349

 control strategy 345
 framework 344
 process 343, 344
 risk analysis 347–348
 risk evaluation and control 348
 risk identification/hazard identification 345–347
 robust method 245, 312
 robustness and method operable design region (MODR) 226–227
 robustness testing
 analytical method 302
 computer-assisted robustness study 304–312
 experimental design
 experiments and determination of responses 325–327
 factor levels 315–318
 matrix 322–326
 statistical and graphical evaluation 326–328
 factors and tolerances 311
 time-dependent and intrinsic parameters 302–304
 root mean square error (RMSE) 125, 178, 183–184, 199, 288, 363, 490, 492, 493

s

sample suitability assessment (SSA) 111, 473, 488
 Savitzky-Golay smoothing technique 272
 signal-to-noise ratio 55, 195, 198, 270, 273, 363, 364, 490
 significance tests 111, 121, 149–151, 156, 163, 167, 184, 188, 438
 single-point calibration 114, 189–190, 361, 375, 377, 380, 382, 401
 singular value decomposition (SVD) 273, 277
 soft independent modeling of class analogies (SIMCA) 285
 spiking study procedure
 impurities/degradants 158–160

integration mode accuracy 158–159
 percentage recovery 155–156
 recovery function 156–157
 response factors 159–160
 standard addition 157
 SST/SSA failures 488
 standard normal variate (SNV) 271
 standard operating procedure (SOP) 48,
 292, 436, 493
 statistical significance test 156, 163, 438
 student-*t*-distribution 104–106
 supercritical fluid chromatography (SFC)
 242
 support vector machines (SVM) 284
 systematic errors 89, 90, 97, 98, 109, 147,
 164, 176, 182, 186–187, 189, 288,
 361
 systematic monitoring program 493–495
 system precision 112, 113, 119, 121, 123,
 129, 135, 137, 147, 366, 375, 380,
 386–387, 448, 488
 system suitability test (SST) 16, 27, 51,
 53, 58, 108, 113, 143, 182, 195, 205,
 228, 259, 303, 328, 366, 441, 447,
 473, 488, 490

t

target measurement uncertainty, in ATP
 79, 80, 83–85, 87–90, 95
 thin layer chromatography (TLC) 171
 threshold of toxicological concern (TCC)
 194
 time synchronisation 25
 tolerance interval 85, 134, 161, 366, 367,
 429–431, 471, 473, 507
 trending 266, 290, 436, 487
 two one-sided *t*-tests (TOST) 152, 484

U

United States Pharmacopeia (USP)
 38–39
 apparatus, instruments and systems
 40–41
 data quality triangle 39
 4Qs model 39–40
 lifecycle 219
 roles and responsibilities 42–43
 upper specification limit (USL) 130, 131,
 143, 358, 449, 453
 user requirement specifications (URS)
 52

V

validation HPLC methodology
 accuracy of MC 384–385
 calibration model 384
 specificity 380–382
 validation tests, ICH Q2
 accuracy 364
 precision 365–366
 range, lower range limits 363
 range, response 361–362
 robustness 367
 validity, invalids 42, 205, 268, 420, 459,
 488, 494ff, 504
 variable importance in projection (VIP)
 274
 variable selection 265, 273–275
 visualization charts 496–501

W

water content method 461–465
 weighted linear regression 187–189
 weighted regression 178, 189
 worst-case scenario 131–132









